Immunohistochemical Staining and Sarcomatoid Mesothelioma: Beyond the Lab
When it comes to understanding individual cases of sarcomatoid mesothelioma, doctors should not rely too heavily on immunohistochemical staining. That conclusion comes from mesothelioma researchers at MD Anderson Cancer Center in Texas. The researchers just released a new study focused on this rare mesothelioma subtype. A patient’s subtype has an impact on what kind of treatment could work best for them. Sarcomatoid mesothelioma is usually less responsive to chemotherapy. Immunohistochemical staining is a pathology technique. It is the main way that doctors tell the difference between mesothelioma subtypes. But the MD Anderson report suggests that not all cases of sarcomatoid mesothelioma are created equal. The researchers say it is important to look beyond the lab findings to understand individual cases….